Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan; Department of Psychiatry, Kodama Hospital, Ishinomaki, Miyagi, Japan.
Department of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan.
Schizophr Res. 2024 Jun;268:98-106. doi: 10.1016/j.schres.2023.06.003. Epub 2023 Jun 16.
Higher frequencies of inflammatory adverse effects of clozapine have been reported in Japan. As the international titration protocol for Asians has set slower dose titration than the Japanese package insert, we hypothesized that a dose titration speed slower than the recommendation of the guideline would be associated with fewer inflammatory-related adverse events.
The medical records of all 272 patients who were first started on clozapine at seven hospitals between 2009 and 2023 were studied retrospectively. Of those, 241 were included in the analysis. The patients were divided into two groups regarding whether the titration speed was faster or slower than the guideline for Asians. The incidence of inflammatory adverse events with clozapine was compared between the groups.
The frequency of inflammatory adverse events was 34 % (37/110) in the faster titration group and 13 % (17/131) in the slower titration group, and a significant difference was observed by Fisher exact test (odds ratio 3.38; 95 % confidence interval 1.71-6.91; p < 0.001). Serious adverse effects, fever for more than five days, and clozapine discontinuation were significantly more frequent in the faster titration group. Logistic regression analysis indicated significantly more inflammatory adverse events in the faster titration group (adjusted odds ratio 4.01; 95 % confidence interval 2.02-7.87; p < 0.001) considering age, sex, body mass index, concomitant valproic acid, and smoking as confounding factors.
Clozapine-induced inflammatory adverse events were less frequent in Japanese individuals when a titration rate was more gradual than the protocol recommended in the Japanese package insert.
在日本,氯氮平的炎症不良反应频率较高。由于亚洲人的国际滴定方案设定的剂量滴定速度慢于日本说明书,我们假设低于指南推荐的剂量滴定速度与较少的炎症相关不良事件有关。
回顾性研究了 2009 年至 2023 年期间在七家医院首次开始使用氯氮平的 272 名患者的病历。其中,241 名患者纳入分析。根据剂量滴定速度是否快于亚洲人指南将患者分为两组。比较两组氯氮平引起的炎症不良事件发生率。
在快速滴定组中,炎症不良事件的发生率为 34%(37/110),在缓慢滴定组中为 13%(17/131),Fisher 确切检验有显著差异(优势比 3.38;95%置信区间 1.71-6.91;p<0.001)。在快速滴定组中,严重不良事件、发热超过五天和氯氮平停药的发生率显著更高。Logistic 回归分析表明,在快速滴定组中炎症不良事件明显更多(调整后的优势比 4.01;95%置信区间 2.02-7.87;p<0.001),考虑到年龄、性别、体重指数、合并使用丙戊酸和吸烟作为混杂因素。
与日本说明书中推荐的方案相比,当剂量滴定速度更缓慢时,日本个体中氯氮平引起的炎症不良反应频率较低。